Hostname: page-component-5b777bbd6c-sbgtn Total loading time: 0 Render date: 2025-06-18T14:57:38.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Brexpiprazole Use for Agitation in Parkinson’s Disease Dementia Without Causing Drug-Induced Parkinsonism

Published online by Cambridge University Press:  19 May 2025

Melek Kandemir Yilmaz Open the ORCID record for Melek Kandemir Yilmaz [Opens in a new window]
Melek Kandemir Yilmaz*
Affiliation:
Department of Neurology, Bodrum American Hospital, Mugla, Türkiye
*
Email: melekkandemir@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

agitationbrexpiprazoleParkinson’s diseaseParkinson’s disease dementia
Type
Letter to the Editor: New Observation
Information
Canadian Journal of Neurological Sciences , First View , pp. 1 - 2
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Carrarini, C, Russo, M, Dono, F, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol. 2021;12:644317. DOI: 10.3389/fneur.2021.644317.Google Scholar
Brexpiprazole FDA drug data. Access date: 03/29/2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205422s009lbl.pdf Google Scholar
Hope, J, Castle, D, Keks, NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018;26:92–4. DOI: 10.1177/1039856217732473.Google Scholar
Lee, D, Slomkowski, M, Hefting, N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80:1307–16. DOI: 10.1001/jamaneurol.2023.3810.Google Scholar
Sanagawa, A, Shiraishi, N, Sekiguchi, F, Akechi, T, Kimura, K. Successful use of brexpiprazole for Parkinson’s disease psychosis without adverse effects: a case report. J Clin Psychopharmacol. 2019;39:685–7. DOI: 10.1097/JCP.0000000000001127.Google Scholar
Jackowiak, EM, Chou, KL. Severe parkinsonism caused by brexpiprazole: a case report. Parkinsonism Relat Disord. 2019;69:138–9. DOI: 10.1016/j.parkreldis.2019.11.013.Google Scholar
Lee, C, Shih, SH, Shen, YC. Successful use of high-dose brexpiprazole for psychosis in Lewy body dementia without adverse effects. Psychiatry Clin Psychopharmacol. 2024;34:99–101. DOI: 10.5152/pcp.2024.23772.Google Scholar